Skip to main content

Eliem Therapeutics, Inc. (ELYM)

NASDAQ: ELYM · Delayed Price · USD
15.23 -1.17 (-7.13%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap386.21M
Revenue (ttm)n/a
Net Income (ttm)-37.35M
Shares Out25.36M
EPS (ttm)-1.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume348,184
Open16.42
Previous Close16.40
Day's Range15.00 - 17.03
52-Week Range13.65 - 29.69
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About ELYM

Eliem Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic pot...

IndustryBiotechnology
IPO DateAug 10, 2021
CEORobert Azelby
Employees25
Stock ExchangeNASDAQ
Ticker SymbolELYM
Full Company Profile

Financial Performance

Financial Statements

News

Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months

1 week ago - GlobeNewsWire

Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to ...

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neurona...

1 month ago - GlobeNewsWire

Eliem Therapeutics Announces Pricing of Initial Public Offering

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability ...

1 month ago - GlobeNewsWire

Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public

Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO.

2 months ago - GeekWire

Nervous System Firm Eliem Therapeutics Files For $80M IPO

Eliem Therapeutics (NASDAQ: ELYM), a Phase 2a biotech developing therapies for neuronal excitability disorders, filed an IPO prospectus with the SEC to raise up to $80 million. Its two lead candidates a...

2 months ago - Benzinga

Nervous system biotech Eliem Therapeutics files for an $80 million IPO

Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, filed on Friday with the SEC to raise up to $80 million.

2 months ago - NASDAQ

Eliem Therapeutics IPO Registration Document (S-1)

Eliem Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC